View in EDS

1057P Preliminary pharmacokinetics (PK), safety and efficacy of two dosing regimens of CS1003 (anti-PD-1) in solid tumours: 200 mg every 3-week (Q3W) and 400 mg every 6-week (Q6W) dosing.

Saved in:
Bibliographic Details
Title: 1057P Preliminary pharmacokinetics (PK), safety and efficacy of two dosing regimens of CS1003 (anti-PD-1) in solid tumours: 200 mg every 3-week (Q3W) and 400 mg every 6-week (Q6W) dosing.
Authors: Markman, B.1 (AUTHOR), Day, D.1 (AUTHOR), Park, J.J.W.2 (AUTHOR), Coward, J.3 (AUTHOR), Bishnoi, S.4 (AUTHOR), Kotasek, D.4 (AUTHOR), Eek, R.5 (AUTHOR), Brown, M.P.6 (AUTHOR), Lemech, C.7 (AUTHOR), Kuo, J.7 (AUTHOR), Prawira, A.8 (AUTHOR), Strother, R.9 (AUTHOR), Zhang, Q.10 (AUTHOR), Wang, L.11 (AUTHOR), Chen, R.11 (AUTHOR), Ma, Y.11 (AUTHOR), Qin, Z.11 (AUTHOR), Tse, A.10 (AUTHOR)
Source: Annals of Oncology. 2020 Supplement 4, Vol. 31, pS722-S722. 1p.
Database: Academic Search Ultimate
FullText Text:
  Availability: 0
Header DbId: asn
DbLabel: Academic Search Ultimate
An: 152695711
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: 1057P Preliminary pharmacokinetics (PK), safety and efficacy of two dosing regimens of CS1003 (anti-PD-1) in solid tumours: 200 mg every 3-week (Q3W) and 400 mg every 6-week (Q6W) dosing.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AR" term="%22Markman%2C+B%2E%22">Markman, B.</searchLink><relatesTo>1</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Day%2C+D%2E%22">Day, D.</searchLink><relatesTo>1</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Park%2C+J%2EJ%2EW%2E%22">Park, J.J.W.</searchLink><relatesTo>2</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Coward%2C+J%2E%22">Coward, J.</searchLink><relatesTo>3</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Bishnoi%2C+S%2E%22">Bishnoi, S.</searchLink><relatesTo>4</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Kotasek%2C+D%2E%22">Kotasek, D.</searchLink><relatesTo>4</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Eek%2C+R%2E%22">Eek, R.</searchLink><relatesTo>5</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Brown%2C+M%2EP%2E%22">Brown, M.P.</searchLink><relatesTo>6</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Lemech%2C+C%2E%22">Lemech, C.</searchLink><relatesTo>7</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Kuo%2C+J%2E%22">Kuo, J.</searchLink><relatesTo>7</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Prawira%2C+A%2E%22">Prawira, A.</searchLink><relatesTo>8</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Strother%2C+R%2E%22">Strother, R.</searchLink><relatesTo>9</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Zhang%2C+Q%2E%22">Zhang, Q.</searchLink><relatesTo>10</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Wang%2C+L%2E%22">Wang, L.</searchLink><relatesTo>11</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Chen%2C+R%2E%22">Chen, R.</searchLink><relatesTo>11</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Ma%2C+Y%2E%22">Ma, Y.</searchLink><relatesTo>11</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Qin%2C+Z%2E%22">Qin, Z.</searchLink><relatesTo>11</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Tse%2C+A%2E%22">Tse, A.</searchLink><relatesTo>10</relatesTo> (AUTHOR)
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22Annals+of+Oncology%22">Annals of Oncology</searchLink>. 2020 Supplement 4, Vol. 31, pS722-S722. 1p.
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=asn&AN=152695711
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1016/j.annonc.2020.08.1177
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        PageCount: 1
        StartPage: S722
    Titles:
      – TitleFull: 1057P Preliminary pharmacokinetics (PK), safety and efficacy of two dosing regimens of CS1003 (anti-PD-1) in solid tumours: 200 mg every 3-week (Q3W) and 400 mg every 6-week (Q6W) dosing.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Markman, B.
      – PersonEntity:
          Name:
            NameFull: Day, D.
      – PersonEntity:
          Name:
            NameFull: Park, J.J.W.
      – PersonEntity:
          Name:
            NameFull: Coward, J.
      – PersonEntity:
          Name:
            NameFull: Bishnoi, S.
      – PersonEntity:
          Name:
            NameFull: Kotasek, D.
      – PersonEntity:
          Name:
            NameFull: Eek, R.
      – PersonEntity:
          Name:
            NameFull: Brown, M.P.
      – PersonEntity:
          Name:
            NameFull: Lemech, C.
      – PersonEntity:
          Name:
            NameFull: Kuo, J.
      – PersonEntity:
          Name:
            NameFull: Prawira, A.
      – PersonEntity:
          Name:
            NameFull: Strother, R.
      – PersonEntity:
          Name:
            NameFull: Zhang, Q.
      – PersonEntity:
          Name:
            NameFull: Wang, L.
      – PersonEntity:
          Name:
            NameFull: Chen, R.
      – PersonEntity:
          Name:
            NameFull: Ma, Y.
      – PersonEntity:
          Name:
            NameFull: Qin, Z.
      – PersonEntity:
          Name:
            NameFull: Tse, A.
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 02
              M: 09
              Text: 2020 Supplement 4
              Type: published
              Y: 2020
          Identifiers:
            – Type: issn-print
              Value: 09237534
          Numbering:
            – Type: volume
              Value: 31
          Titles:
            – TitleFull: Annals of Oncology
              Type: main
ResultId 1